bluebird bio Announces Pricing of Public Offering of Common Stock
December 12 2017 - 7:46PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage
biotechnology company committed to developing potentially
transformative gene therapies for severe genetic diseases and
cancer, today announced the pricing of an underwritten public
offering of 3,243,244 shares of its common stock at a public
offering price of $185 per share, before underwriting discounts. In
addition, bluebird bio has granted the underwriters a 30-day option
to purchase up to an additional 486,486 shares of common stock. All
of the shares in the offering are to be sold by bluebird bio.
Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan
Securities LLC and Cowen are acting as joint book-running managers
of the offering. The offering is expected to close on or about
December 15, 2017, subject to customary closing conditions.
bluebird bio anticipates the total gross proceeds from the
offering (before deducting underwriters’ discounts and commissions
and estimated offering expenses) will be approximately $600
million, excluding any exercise of the underwriters’ option to
purchase additional shares.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on December 11, 2017.
The final prospectus supplement relating to the offering will be
filed with the SEC and will be available on the SEC’s website at
www.sec.gov. When available, copies of the final prospectus
supplement and the accompanying prospectus relating to these
securities may also be obtained by contacting one of the following:
Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West
Street, New York, NY 10282, telephone: (212) 902-1171,
facsimile: (212) 902-9316, email:
prospectus-ny@ny.email.gs.com; BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, email:
dg.prospectus_requests@baml.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (866) 803-9204; or Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at
(631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy
expertise and gene editing capabilities, bluebird bio has built an
integrated product platform with broad potential application to
severe genetic diseases and cancer. bluebird bio's gene therapy
clinical programs include its Lenti-D™ product candidate, currently
in a Phase 2/3 study, called the Starbeam Study, for the treatment
of cerebral adrenoleukodystrophy, and its LentiGlobin® product
candidate, currently in five clinical studies for the treatment of
transfusion-dependent β-thalassemia, also known as β-thalassemia
major, and severe sickle cell disease. bluebird bio's oncology
pipeline is built upon the company's leadership in lentiviral gene
delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor
(CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead
oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs
partnered with Celgene. bb2121 and bb21217 are each currently being
studied in Phase 1 trials for the treatment of relapsed/refractory
multiple myeloma. bluebird bio also has discovery research programs
utilizing megaTALs/homing endonuclease gene editing technologies
with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts,
Seattle, Washington, Durham, North Carolina and Europe.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the anticipated final terms, timing and completion of the
proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the proposed public
offering, that the preliminary results from our clinical trials
will not continue or be repeated in our ongoing clinical trials,
the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates,
the risk of a delay in the enrollment of patients in our clinical
studies, the risks that the changes we have made in the LentiGlobin
drug product manufacturing process or the HGB-206 clinical study
protocol will not result in improved patient outcomes, risks that
the current or planned clinical studies of the LentiGlobin drug
product will be insufficient to support regulatory submissions or
marketing approval in the United States and European Union, risks
that the current clinical study of Lenti-D will be insufficient to
support regulatory submissions or marketing approval in the United
States and European Union, the risk that our collaborations,
including the collaboration with Celgene, will not continue or will
not be successful, and the risk that any one or more of our product
candidates will not be successfully developed, approved or
commercialized. There can be no assurance that bluebird bio will be
able to complete the proposed public offering on the anticipated
terms, or at all. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our annual report on Form 10-K and our most recent quarterly
report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171212006490/en/
Investor Relations and Mediabluebird bio, Inc.Elizabeth
Pingpank, 617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024